CONSORT flow diagram: disposition of study participants. After cycle 1, patients (except those with progressive disease [PD]) were re-treated with two to 16 additional cycles, limited to two past documentations of complete remission (CR) or earlier at the time immunogenicity was documented. In total, 114 cycles were administered to 28 patients, and re-treated patients achieved CR or partial remission (PR) or had stable disease (SD). QOD, every other day.